Wize Pharma (וויז פארמה בע"מ) is a clinical-stage biopharmaceutical company focusing on the treatment of ophthalmic disorders, including dry eye syndrome (DES), Sjögren’s syndrome, and conjunctivochalasis. It has the rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses.